US Pharma MarketingThe FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
Gilead’s growing HIV franchise; cell therapy licensing deals plummet is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Source: PharmaVoice